Track topics on Twitter Track topics that are important to you
March 14, 2018 (Investorideas.com Newswire) Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm.
Original Article: Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'NEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...